Introduction
It is said to be abused when a substance is utilized in a way, environment, quantity, or frequency that could be hazardous to the person or people around them (Selseng et al., 2021). It has been emphasized in several strategies, programs, and pronouncements that user involvement in drug use care is a core goal of welfare services. The research on substance use disorders (SUDs) and care emphasises the need for user involvement, but there are also many connected difficulties. The planning of drug use services involves several parameters, most of which are obtained from the viewpoint of experts.
Literature Review
Traditionally, services for preventing other mental health and overall healthcare services, treating drug abuse and substance use problems, have been offered. Weak and underdeveloped approaches exist for involving those who have had drugs in developing substance use services (Hyshka et al., 2017). Since preventative services were previously not seen as the responsibility of healthcare systems, people in need of care for substance abuse disorders only had access to a significantly limited range of treatment options that were usually not reimbursed by insurance. (Press et al., 2016). Integrating prevention, intervention, and rehabilitation programs into healthcare systems is the most effective way to address substance use and its impacts. Additionally, it offers the best chance of improving treatment quality and access. Healthcare reform laws and numerous other trends are making it possible for deeper integration to serve individual and public health better, reduce health disparities, and cut societal costs (Rapp et al., 2006). This shows the initial pre-aspiration to create new opportunities for the implementation of treatment.
It is well-known that most persons with substance use problems do not independently seek treatment frequently because they do not feel they need it or they feel unprepared for it. Other times, individuals with substance use disorders may be unaware of a need or do not know how to access treatment. However, people with addiction problems frequently seek medical attention for other reasons (Selseng et al., 2021). The team of treatment professionals plays an essential role in dealing with patient substance abuse issues. For instance, the results of the study by Meier et al. (2006) highlight the significance of treatment professionals paying attention to the therapeutic alliance in drug treatment, as counselors’ alliance assessments were discovered to be among the most powerful predictors of dropout.
Through the use of alliance measurements as therapeutic tools, treatment practitioners may gain early insight into the possibility of disengagement. Prospective studies are needed to ascertain whether policies that move clients with problematic alliances to different counselors improve client retention (Meier et al., 2006). Everyone eventually goes through periods of anxiety, melancholy, loneliness, shame, and guilt. People in recovery cannot escape these feelings more than others since they are normal. Therefore, the task in recovery is to embrace negative emotions and learn how to “cope with” or “manage” them rather than deny that they exist. Moreover, the opposite situation has many negative outcomes (Neale et al., 2015). They may be associated with changes in behavior and social activity.
Other potentially harmful outcomes of purportedly successful recovery included engaging in therapies that required constant term and thus prohibited closure, avoiding social situations to prevent relapse but later developing loneliness and reclusiveness. Moreover, it consists of forming close bonds with peers in recovery who later relapsed, “taking you with them,” and seeking support from peer support groups and meetings only to develop an “addiction” to those meetings (Bacha et al., 2020). Thus, in reality, there are no significant positive changes.
Opioid replacement therapy (OST) based on methadone or buprenorphine is a well-known treatment with favorable effects on mortality, health and social issues, and criminality among those with opioid dependence. Methadone and buprenorphine abuse can positively affect patients’ health and their legal situation (Noble & Mari, 2019). According to a Harris and Rhodes study, using illicit methadone may act as a “protective strategy” that enables persons with drug addictions to control their drug usage, enhance their social interactions, and guard themselves against hepatitis C. When compared to heroin usage, the use of buprenorphine illicitly can lower health risks and enhance the quality of life (Amato et al., 2011). However, it is necessary to constantly monitor the condition of a person so that he does not cross a certain line of accessibility.
Since the 1970s, opioid substitution therapy, as opposed to abstinence, has been advised to treat opiate addiction during pregnancy. In 1998, a panel of experts suggested that Methadone Maintenance Treatment (MMT) will be accessible to pregnant women. The most often given synthetic opioid for replacement therapy during pregnancy was and remained methadone (Dennis et al., 2003). Opioid changing to methadone is regularly reported to improve pain management in patients with an undesirable equilibrium between pain control and adverse reactions when receiving first-line opioid treatment. However, it entails a risk of drug buildup and respiratory depression. Less dangerous treatments must be tried first to justify this risk, as well as the fact that a sizable enough percentage of patients see a sustained improvement in pain management (White & Kelly, 2011). Owing to the effect of substance use, in the present report, opioid substitution treatment with methadone among different participants was accessed.
Methods
In this project, structured interviews with Opioid Substitution Treatment (OST) patients were done. The sites were chosen to represent a variety of local drug scenes and varying access to OST, and 24 participants were interviewed. The majority (n=20, 83%) were receiving methadone-assisted opioid replacement therapy. The location of most interviews (n=16, 67%) was the general practitioner. At a charity, eight interviews (or 33%) were conducted. The interview duration ranged from 14 to 44 minutes, with an average of 28 minutes (SD = 8.6). A manual, three-step qualitative textual analysis was used for the analysis. Based on the major themes in the interview protocol, we first performed a brief coding after carefully reading the material. Then, using a second, more in-depth coding, we determined how the themes had changed and remained the same through time. Finally, we reviewed the content to locate pertinent representative and instructive quotes.
Results
There was wide diversity among the sample regarding personal circumstances, the level of drug usage, and its effects. Some spoke of life situations defined by housing issues and support systems centered on criminality, marginalization, and severe drug addictions. Others explained how they had managed to lead a somewhat well-structured existence with consistent housing and employment despite drug usage leading to physical dependence. Some people hide their drug usage from their loved ones, friends, and co-workers.
Discussion
Abuse is the term used to describe the use of alcohol or other drugs in a manner, setting, quantity, or frequency that puts the user or those nearby at risk. Alcoholism, drug addiction, and other disorders associated with substance use affect millions of Americans and are significantly expensive for society (Selseng et al., 2021). Although there is a risk of drug build-up and respiratory depression, moving from first-line opioids to methadone is regularly reported to enhance pain control in individuals with an undesirable equilibrium between pain control and adverse reactions. A sufficient number of patients must see a sustained improvement in pain management to justify this risk, as well as the prior use of less dangerous treatments (Madden et al., 2008). Accordingly, the use of several medications should be supervised by specialists to avoid relapses.
Opiate substitution therapy (with methadone, l-a acetyl methanol (LAAM), or buprenorphine) is defined by FDA regulations as treatment with an authorized opiate that lasts longer than 30 days. A person with an addiction cannot start methadone maintenance therapy unless they exhibit physiological indicators of a current addiction (withdrawal symptoms) and can prove a one-year history of addiction (Noble & Marie, 2019). Given concerns about prenatal exposure, birth outcomes, and the need to regulate dose, pharmacotherapy, primarily opiate-substitution therapies carefully, has tackled the use of drugs in the treatment of pregnant women. Opioid-dependent pregnant and postpartum women require careful consideration when receiving pharmacological treatment, including assessment, choosing the best maintenance medication, induction and stabilization, and medication management concerning the different periods of pregnancy and other related issues (Dennis et al., 2003). This is necessary to avoid possible negative consequences on human health.
Conclusion
Almost all of the participants in the study shared the sentiment that the Opioid Substitution Treatment (OST) program imposes a significant amount of authority and control measures on patients. Some even described the treatment as demeaning and felt that it stripped them of their autonomy. One of the main issues that was brought up was the fact that patients are required to be at a specific location at a specific time to receive their medication. This can be particularly challenging for those who have work or family obligations that make it difficult for them to make it to the clinic on time. Additionally, the rules of the program stipulate that the drug must be taken for the first six months under medical supervision at the clinic, which can be seen as an infringement on patients’ rights to privacy and self-determination. Overall, the participants in the study felt that the OST program’s strict rules and regulations were a source of frustration and disappointment.
References
Amato, L., Minozzi, S., Davoli, M., & Vecchi, S. (2011). Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database of Systematic Reviews. Web.
Bacha, K., Hanley, T., & Winter, L. A. (2019). ‘Like a human being, I was an equal, I wasn’t just a patient’: Service users’ perspectives on their experiences of relationships with staff in mental health services. Psychology and Psychotherapy: Theory, Research, and Practice, 93(2), 367–386. Web.
Dennis, M., Scott, C. K., & Funk, R. (2003). An experimental evaluation of recovery management checkups (RMC) for people with chronic substance use disorders. Evaluation and Program Planning, 26(3), 339–352. Web.
Hyshka, E., Karekezi, K., Tan, B., Slater, L. G., Jahrig, J., & Wild, T. C. (2017). The role of consumer perspectives in estimating population needs for substance use services: a scoping review. BMC Health Services Research, 17(1). Web.
Madden, A., Lea, T., Bath, N., & Winstock, A. R. (2008). Satisfaction guaranteed? What do clients on methadone and buprenorphine think about their treatment? Drug and Alcohol Review, 27(6), 671–678. Web.
Meier, P. S., Donmall, M. C., McElduff, P., Barrowclough, C., & Heller, R. F. (2006). The role of the early therapeutic alliance in predicting drug treatment dropout. Drug and Alcohol Dependence, 83(1), 57–64. Web.
Neale, J., Tompkins, C., Wheeler, C., Finch, E., Marsden, J., Mitcheson, L., Rose, D., Wykes, T., & Strang, J. (2015). “You’re all going to hate the word ‘recovery’ by the end of this”: Service users’ views of measuring addiction recovery. Drugs: Education, Prevention & Policy, 22(1), 26–34. Web.
Noble, F., & Marie, N. (2019). Management of opioid addiction with opioid substitution treatments: Beyond methadone and buprenorphine. Frontiers in Psychiatry, 9. Web.
Press, K. R., Zornberg, G. Z., Geller, G., Carrese, J., & Fingerhood, M. I. (2015). What patients with addiction disorders need from their primary care physicians: A qualitative study. Substance Abuse, 37(2), 349–355. Web.
Rapp, R. C., Xu, J., Carr, C. A., Lane, D. T., Wang, J., & Carlson, R. (2006). Treatment barriers identified by substance abusers are assessed at a centralized intake unit. Journal of Substance Abuse Treatment, 30(3), 227–235. Web.
Selseng, L. B., Follevåg, B. M., & Aaslund, H. (2021). How people with lived experiences of substance use understand and experience user involvement in substance use care: A synthesis of qualitative studies. International Journal of Environmental Research and Public Health, 18(19), 10219. Web.